The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 7 March 2006, www.theannals.com, DOI 10.1345/aph.1G367.
 The Annals of Pharmacotherapy: Vol. 40, No. 4, pp. 689-693. DOI 10.1345/aph.1G367
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tafreshi, M. J
Right arrow Articles by Fisher, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tafreshi, M. J
Right arrow Articles by Fisher, E.

NEW DRUG APPROVALS

Ranolazine: A New Approach to Management of Patients with Angina

Mohammad J Tafreshi, PharmD BCPS

Associate Professor, Director, Cardiology Pharmacy Practice Residency, Midwestern University College of Pharmacy—Glendale, Glendale, AZ

Edward Fisher, BSPharm PhD

Professor, Midwestern University College of Pharmacy—Glendale

Reprints: Dr. Tafreshi, MWU-CPG, 19555 N. 59th Ave., Glendale, AZ 85308-6813, fax 623/572-3550, mtafre{at}midwestern.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, and clinical efficacy of ranolazine for the treatment of chronic stable angina.

DATA SOURCES: MEDLINE was searched (1966-February 2006) using the English-language key terms ranolazine and chronic stable angina. Additional studies were identified from the bibliographies of the reviewed literature.

STUDY SELECTION AND DATA EXTRACTION: Studies evaluating ranolazine, alone or in combination with other agents, were incorporated in this review.

DATA SYNTHESIS: Ranolazine is a metabolic modulator designed to improve cardiac energy availability and cardiac metabolism. It is believed to be a partial fatty acid oxidation inhibitor. Ranolazine has been shown to improve exercise duration and time to anginal attacks without significantly affecting heart rate or blood pressure. Adverse effects of ranolazine are reported to be dose related. The elimination half-life of ranolazine is estimated to be between 1.4 and 1.9 hours for the immediate-release and 7 hours for sustained-release preparations.

CONCLUSIONS: Ranolazine has a unique mechanism of action that is different from that of conventional agents. It has been studied as monotherapy or in combination with other commonly prescribed agents. It appears that ranolazine has a promising safety data profile and does not affect hemodynamic parameters. At this point, although ranolazine should not be used in place of conventional therapy, it appears that ranolazine may be considered in the management of symptomatic patients when standard antianginal medications are not tolerated or are ineffective.

Key Words: angina, ranolazine

Published Online, March 7, 2006. www.theannals.com, DOI 10.1345/aph.1G367




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.